Showing results (1881-1890 of 1,905) with videos related to

Sort By:
Pageof 191
Human Molecular Genetics|October 13, 2011
Long-range DNA looping and gene expression analyses identify DEXI as an autoimmune disease candidate geneLucy J Davison, Chris Wallace, Jason D Cooper, et al.
Trends in Ecology & Evolution|September 29, 2015
Archiving Primary Data: Solutions for Long-Term StudiesJames A Mills, Céline Teplitsky, Beatriz Arroyo, et al.
The Journal of Pathology|December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomasKarolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastasesNicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
Science (New York, N.Y.)|July 16, 2005
The genome of the kinetoplastid parasite, Leishmania majorAlasdair C Ivens, Christopher S Peacock, Elizabeth A Worthey, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|August 1, 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium studyPeter F Rambau, Robert A Vierkant, Maria P Intermaggio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Pageof 191